B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price ...

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthcare Services (HCSG – Research Report) and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DOJoPAWP.js ...

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared ...

Former India fast bowler and Lucknow Super Giants mentor Zaheer Khan has stressed the importance of having Mayank Yadav at his 150% fitness before fielding him in the upcoming IPL 2025. Listen to ...

A long sprint from the deep. A euphoric leap. A jubilant scream. Is this the real Mayank Agarawal? Indeed, the situation demanded exultation. Abhilash Shetty had claimed Vidarbha’s last wicket ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $236.00. The company ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of $20.00. The company’s shares closed yesterday at $7.00.